Actively Recruiting
Pharmacogenomics-Supported Psychotropic Prescribing Trial: A Pilot Implementation Study in Manitoba
Led by University of Manitoba · Updated on 2025-09-08
200
Participants Needed
2
Research Sites
104 weeks
Total Duration
On this page
Sponsors
U
University of Manitoba
Lead Sponsor
U
University of Calgary
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating the feasibility and usefulness of pharmacogenetic (PGx) testing for adults aged 18 and older seeking care for mental illness in Manitoba. PGx testing uses genetic information to guide medication selection and dosing, potentially reducing the trial-and-error process when prescribing psychotropic medicines. This study aims to explore how well PGx testing can be integrated into mental health care and its impact on clinical decisions and patient outcomes in this population. Participants will undergo pharmacogenetic testing by providing a small saliva sample. The extracted DNA is analyzed for specific gene variants related to drug metabolism and response. Results are compiled into a detailed clinical report with evidence-based recommendations to help physicians tailor psychotropic medication choices. This testing panel includes multiple genes such as CYP2C19, CYP2D6, and others relevant to psychiatric drug response, and results are shared with treating clinicians to inform treatment decisions. During the study, participants and clinicians will complete satisfaction surveys, and researchers will track test turnaround times and how results affect prescribing patterns. Various clinical assessments, including symptom severity and global functioning scales, will be performed at baseline and up to three months after to evaluate changes. Additional measures include adverse drug reaction ratings and healthcare resource use over one year. The study seeks to inform healthcare policy and support decisions on implementing PGx-guided psychotropic prescribing in Manitoba.
CONDITIONS
Brief Title
Pharmacogenomics-Supported Psychotropic Prescribing Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Psychotropic medication initiation, change, dose adjustment, or augmentation is indicated
- Treating clinician believes PGx testing may benefit and refers the patient to the study
You will not qualify if you...
- Unwilling to provide saliva samples for genetic testing
- History of liver or bone marrow transplantation
- Pharmacogenetic testing results already available
- No personal health identification number (PHIN) available
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 months
Participants provide a saliva sample for genetic testing to help guide medication selection and dosing.
1 baseline visit
Duration - 3 months
Participants are assessed for clinical symptoms, medication side effects, and healthcare utilization over time to evaluate the impact of pharmacogenetic testing.
1 follow-up visit approximately 3 months after baseline
Trial Site Locations
Total: 2 locations
1
Shared Health Facilities
Winnipeg, Manitoba, Canada, R3C 3H8
Not Yet Recruiting
2
University of Manitoba College of Pharmacy
Winnipeg, Manitoba, Canada, R3E 0T5
Actively Recruiting
Research Team
A
Abdullah Al Maruf, BPharm, MPharm, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here